- Home
- MLR vs CMRX Comparison
MLR vs CMRX Comparison
Compare MLR & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLR
- CMRX
- Stock Information
- Founded
- MLR 1990
- CMRX 2000
- Country
- MLR United States
- CMRX United States
- Employees
- MLR N/A
- CMRX N/A
- Industry
- MLR Construction/Ag Equipment/Trucks
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- MLR Consumer Discretionary
- CMRX Health Care
- Exchange
- MLR Nasdaq
- CMRX Nasdaq
- Market Cap
- MLR 776.7M
- CMRX 797.3M
- IPO Year
- MLR 1994
- CMRX 2013
- Fundamental
- Price
- MLR $41.10
- CMRX N/A
- Analyst Decision
- MLR Strong Buy
- CMRX Hold
- Analyst Count
- MLR 1
- CMRX 4
- Target Price
- MLR $82.00
- CMRX $8.51
- AVG Volume (30 Days)
- MLR 111.4K
- CMRX 1.8M
- Earning Date
- MLR 05-07-2025
- CMRX 05-05-2025
- Dividend Yield
- MLR 1.95%
- CMRX N/A
- EPS Growth
- MLR 7.89
- CMRX N/A
- EPS
- MLR 5.47
- CMRX N/A
- Revenue
- MLR $1,257,500,000.00
- CMRX $212,000.00
- Revenue This Year
- MLR N/A
- CMRX $2,416.04
- Revenue Next Year
- MLR $18.55
- CMRX $923.92
- P/E Ratio
- MLR $7.50
- CMRX N/A
- Revenue Growth
- MLR 9.03
- CMRX N/A
- 52 Week Low
- MLR $37.40
- CMRX $0.75
- 52 Week High
- MLR $78.25
- CMRX $8.55
- Technical
- Relative Strength Index (RSI)
- MLR 41.37
- CMRX 5.34
- Support Level
- MLR $39.20
- CMRX $8.50
- Resistance Level
- MLR $41.99
- CMRX $8.55
- Average True Range (ATR)
- MLR 1.94
- CMRX 0.02
- MACD
- MLR 0.55
- CMRX -0.65
- Stochastic Oscillator
- MLR 69.94
- CMRX 0.00
About MLR Miller Industries Inc.
Miller Industries Inc is engaged in the manufacturing of vehicle towing and recovery equipment. The company produces wreckers, car carriers, and trailer bodies under the Century, Vulcan, Challenger, Holmes, Champion, Chevron, Eagle, Titan, Jige, and Boniface brands. The products are sold in North America, Canada, and Mexico through independent distributors.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.